Inozyme Pharma, Inc.
(NASDAQ GS: INZY)
Rigrodsky Law, P.A. is investigating Inozyme Pharma, Inc. (“Inozyme”) regarding possible breaches of fiduciary duties and other violations of law related to Inozyme’s agreement to be acquired by BioMarin Pharmaceutical Inc. Under the terms of the agreement, Inozyme shareholders will receive $4.00 per share in cash.